Navigation Links
Telik Announces Preclinical Presentations at AACR Annual Meeting
Date:4/7/2008

PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.
Details of the presentations are as follows:

-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors

Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April

13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;

Abstract # 1439

-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human

Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;

Experimental and Molecular Therapeutics 10; Abstract # 2270

-- Identification of a Novel Class of Nonpeptidyl Small-Molecule

Inhibitors of the Human Proteasome; Monday, April 14, 2008,

1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;

Abstract # 3271

-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug

Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer

Chemistry 11; Abstract # 4754

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. DARA Announces Information in Compliance with NASDAQ Rules
3. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
4. VA Announces SGLI and VGLI Premium Reductions
5. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
6. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
7. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
10. Smart Balance Announces Sales Organization Appointments
11. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned ... developed to enhance the health of felines. The formula is all-natural and is made ... in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Research and ... Market for Companion Diagnostic Tests" report to their offering. ... for Companion Diagnostics The World Market for ... personalized medicine diagnostics. Market analysis in the report includes the ... Market (In Vitro Diagnostic Kits) by Region (N. America, EU, ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
Breaking Medicine Technology: